Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
You may also be interested in...
Can An Antibody Cocktail Block COVID-19 Infection? Regeneron’s Warp Speed Research Aims To Find Out Soon
The only non-vaccine project backed by Operation Warp Speed, Regeneron’s antibody cocktail could play a crucial role in the fight against SARS-CoV2 – if it works. Clinical development chief David Weinreich talks to Scrip about its innovative adaptive trial collaboration, and how it could provide answers in a matter of months.
Operation Warp Speed extends its funding beyond vaccines into antibodies, while insiders say friction between Moderna and US government scientists has caused delays.
Cemiplimab was a latecomer to the PD-1/L1 class, but a Phase III success in lung cancer will bring it to the main stage for immuno-oncology.